Pfenex And Hospira Join On Biosimilars | Chemical & Engineering News
Volume 93 Issue 7 | p. 15 | Concentrates
Issue Date: February 16, 2015

Pfenex And Hospira Join On Biosimilars

Department: Business
Keywords: biopharmaceuticals, biosimilars, collaboration

Pfenex, a San Diego-based biotech firm, will work with the generic drug firm Hospira to develop a biosimilar version of Genentech’s eye drug Lucentis. In 2014, sales of Lucentis were about $4 billion. Hospira will pay Pfenex $51 million up front and up to $291 million more in milestone payments. Pfenex’s PF582 monoclonal antibody is in clinical trials to assess its safety and tolerability, and to compare its pharmacokinetics and pharmacodynamics to Lucentis. Pfizer is in the process of acquiring Hospira in a $17 billion deal.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment